Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.

NCT Number	NCT06682728
Lead Sponsor	University of California, Irvine Collaborators: Gilead Sciences
Conditions	Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Enrollment	23 participants
Start Date	2024-11-15
Primary Completion	2026-12-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-30